Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MAGE-A4-specific T-cell engager CDR404

A bispecific T-cell engaging antibody directed against the human leukocyte antigen (HLA)-A2-restricted tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon intravenous administration of the MAGE-A4-specific T-cell engager (TCE) CDR404, the anti-MAGE-A4 moiety targets and binds to MAGE-A4 presented on HLA-A2 on tumor cells and the anti-CD3 moiety binds to CD3- expressing cytotoxic T lymphocytes (CTLs). This selectively cross-links tumor cells and T lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MAGE-A4/anti-CD3 bispecific antibody CDR404
MAGE-A4 M-gager CDR404
MAGE-A4-targeting T-cell engager CDR404
TCE CDR404
Code name:CDR 404
CDR-404
CDR404
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search